Assignment of Product-Specific HCPCS Code for Portrazza® (necitumumab) for Injection

- December 8, 2016
- News
We are sending this communication on behalf of Eli Lilly and Company to announce the assignment of a product‐specific Healthcare Common Procedure Coding System (HCPCS) code for Portrazza® (necitumumab) for injection.
The new code, J9295, is defined as “injection, necitumumab, 1 mg.” This code is effective January 1, 2017.1
Trade Name | HCPCS Code | Strength | NDC* | Effective Date |
Portrazza | J9295 injection, necitumumab, 1 mg | 800 mg/50 mL (16 mg/mL) | 00002-7716-01 | January 1, 2017 |
*Note that the product’s NDC code has been “zero‐filled” to ensure creation of an 11‐digit code that meets CMS standards.
The zero‐fill location is indicated in bold.
NDC=National Drug Code.
Portrazza was approved by the US Food and Drug Administration on November 24, 2015. Portrazza is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Portrazza is not indicated for the treatment of nonsquamous NSCLC.
WARNING: CARDIOPULMONARY ARREST and HYPOMAGNESEMIA
|
Please see here for full Prescribing Information.
For additional information, please visit www.Portrazza.com/hcp.